A systematic review of primary central nervous system lymphoma  

作　　者：Lei Zhang Qingyuan Zhang 

机构地区：[1]Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin,Heilongjiang 150081,China

出　　处：《Holistic Integrative Oncology》2024年第1期517-522,共6页整合肿瘤学(英文)

基　　金：funded by the National Natural Science Foundation of China(Foundation number:8217100680);Key project of Natural Science Foundation of Heilongjiang Province(Fund number:ZD2021H004).

摘　　要：Primary central nervous system lymphoma is a kind of extranodal lymphoma with high degree of malignancy,hidden onset and strong invasion.It is a special type of non-Hodgkin’s lymphoma and very rare in clinic.Due to little under-standing of the pathogenesis and high risk factors of the disease,there are great differences in the prevention,staging and treatment plan of the disease,and there is no strict standard.In this review,we aim to comprehensively summa-rize the clinical characteristics of PCNSL and the promising clinical treatment strategies for PCNSL to date.

关 键 词：PCNSL METHOTREXATE Bruton tyrosine kinase LENALIDOMIDE 

分 类 号：R73[医药卫生—肿瘤]